Chemotherapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), and immune checkpoint inhibitors (ICIs) are currently the main treatments for advanced NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.